This website is for the U.S, for the other countries please refer to this link.

Research Articles
Neurological diseases
Impeto Medical

SUDOSCAN combined to other diagnosis tests to confirm small fiber neuropathy

SUDOSCAN COMBINED TO OTHER DIAGNOSIS TESTS TO CONFIRM SMALL FIBER NEUROPATHY   V. Fabry, A. Gerdelat, B. Acket, P. Cintas, V. Rousseau, E. Uro-Coste, S. M. Evrard and A. Pavy-Le Traon. Article title: “Which Method for Diagnosing Small Fiber Neuropathy?” Front. Neurol., 05 May 2020. In a recent study conducted at Toulouse University Hospital, France,

Read More »
July 30, 2020 No Comments
Diabetes
Impeto Medical

The utility of SUDOSCAN to diagnose diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy

THE UTILITY OF SUDOSCAN TO DIAGNOSE DIABETIC CARDIOVASCULAR AUTONOMIC NEUROPATHY AND DIABETIC POLYNEUROPATHY C. D’amato, C. Greco, G. Lombardo, V. Frattina, M. Campo, C.M.A. Cefalo, V. Izzo, D. Lauro, V. Spallone. Article title: “The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy” J

Read More »
March 11, 2020 No Comments
Diabetes
Impeto Medical

The benefits of SUDOSCAN in early diagnosis of diabetic peripheral neuropathy reviewed in The Lancet

THE BENEFITS OF SUDOSCAN IN EARLY DIAGNOSIS OF DIABETIC PERIPHERAL NEUROPATHY REVIEWED IN THE LANCET Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, Tesfaye S. Article title: “Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention”. The Lancet Diabetes Endocrinol 2019. Volume 7, Issue 12, p938-948, December

Read More »
January 8, 2020 No Comments
Follow-up with SUDOSCAN
Impeto Medical

Longitudinal follow-up with SUDOSCAN

LONGITUDINAL FOLLOW-UP: SUDOSCAN DEMONSTRATED EFFICACY IN RESULTS FOLLOW-UP SUDOSCAN has proven its clinical utility in the follow-up of sudomotor function. In a Finnish study, SUDOSCAN was used to evaluate the effect of physical activity on cardiovascular risk and metabolic diseases.  In patients with the highest level of weekly physical activity (as measured with a pedometer),

Read More »
October 23, 2019 No Comments
Oncology
Impeto Medical

SUDOSCAN in Oncology : Chemotherapy Induced Polyneuropathy

SUDOSCAN in Oncology : Chemotherapy InduCed Polyneuropathy Two studies evaluating SUDOSCAN Severe drug-induced neurotoxic adverse effects constitute the second most common cause of dose limitation after haematological adverse effects.  Chemotherapy Induced Polyneuropathy (CIPN) is commonly associated with platinum analogues, antitubulins (taxane), the proteasome inhibitor bortezomib, and thalidomide. However, it is poorly investigated at an early

Read More »
October 22, 2019 No Comments
News
Impeto Medical

Worldwide Business with kathy ireland® Interviews Impeto Medical to Discuss Their Promising Breakthrough Product for Diabetes Patients and Physicians

Los Angeles, CA – February 14, 2017 — Impeto Medical CEO and Founder Philippe Brunswick is featured on the award-winning, global TV show, Worldwide Business with kathy ireland®. The segment’s topic is the introduction of the company’s innovative, non-invasive SUDOSCAN™ medical device. Impeto Medical is a privately-owned medical device company. The company’s mission is to

Read More »
February 19, 2017 No Comments

More information about SUDOSCAN ?

CONTACT US
Feel free to contact us with your question

Promotional Communication. The medical devices SUDOSCAN is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12

Scroll to Top